Flatiron Health’s Post

Si Wu from my team will present how to use RWD for drug discovery in AACR.

On #InternationalBreastCancerDay, our thoughts are with the patients, healthcare professionals, and researchers. At MEDSIR, we are dedicated to pushing the boundaries of breast cancer research. Founded in 2012 by scientific experts in the development of clinical research, Dr. Javier Cortés Castán, Dr. Antonio Llombart Cussac and Maria Campos, our mission is to create strategic synergies that accelerate the advancement of science. We conduct clinical trials like PHERGain, PARSIFAL, DEBBRAH, ATRACTIB, and MIRADOR, driven by our unwavering commitment to better outcomes for patients with different breast cancer types, including, HER2+, HR+/HER2-, metastatic, TNBC, and more. *Prevention Matters: Breast cancer awareness extends to prevention. We encourage regular medical check-ups, self-examinations, and a healthy lifestyle. By detecting changes early, we can reduce the impact of this disease. To learn more about MEDSIR's clinical trials and their contributions to the field of oncology research, please visit our website: https://www.medsir.org/ #MEDSIR #BreastCancerResearch #ClinicalTrials #Oncology #ScientificInnovation #InnovativeTreatments #Prevention

🎥 Good news! Our latest webinar is now available to watch on demand! In it, you'll learn all about the latest advancements in organ-on-a-chip for cancer research and drug discovery. This webinar will not only cover capturing the tumor microenvironment (TME) in hepatocellular carcinoma in vitro but will explore how MIMETAS can help put therapeutic targets in immuno-oncology into patient context.   In this webinar, you will: - Gain unparalleled insights into replicating TME dynamics in vitro. - Engage in meaningful dialogue about TME complexities, focusing on angiogenesis, stroma, and immune responses. - Understand the impact of TME variables on the success of existing treatments. - Discover how partnership with MIMETAS can impact your oncology research, speeding up discovery and improving therapy prediction accuracy.   Watch the webinar here: https://lnkd.in/eBpNv8YE #CancerResearch #Immunooncology #OncologyResearch

Come see me present at JADPRO Live in Orlando, FL, Nov. 9-12! I present twice - on Saturday and Sunday. I will be presenting with my colleague Grace Baek, PharmD, BCOP! Here are the learning objectives for Saturday's presentation: Learning Objectives: -Study recently approved precision-targeted cancer therapies and their corresponding biomarkers. -Evaluate results of companion diagnostic tests to select appropriate treatments -Follow evidence-based testing guidelines to optimize care for patients with cancer

Join the poster session at the American Association for Cancer Research (AACR) Annual Meeting on April 8 from 9:00 AM to 12:30 PM for a presentation titled: "Harness the power of real-world-data for oncology target and biomarker research: A case study by applying clinic-genomics data for 2,659 lung cancer patients and beyond," presented by AbbVie. Discover how real-world data (RWD) is revolutionizing oncology research! Delve into the comprehensive analysis of 2,659 lung cancer patients, combining ConcertAI electronic health records (EHR) with Caris Life Sciences Lab data. The findings showcase the potential of RWD in identifying unique molecular signatures, analyzing patient treatment patterns, and unlocking personalized medicine. Don't miss out on this session! Learn more: https://hubs.ly/Q02qDnWG0 #AACR #RealWorldData #OncologyResearch

Attend LALCA 2024 to discover advancements in lung cancer therapies, encompassing ongoing clinical trials and comprehensive insights into preclinical and early clinical breakthroughs. Gain invaluable perspectives on addressing critical disparities in the region, arming yourself with actionable insights to drive change and enhance patient outcomes. https://lnkd.in/eBcCzpyR

"Every Deep-Drawn Breath" is a rich blend of science, medical history, profoundly humane patient stories and personal reflection - Vivek Subbiah, MD Wes Ely #Book #Cancer #MedicalHistory #OncoDaily #Oncology #PatientStories

Cancer is a fibrotic disease—and the FDA issued a Letter of Support for the inclusion of our PRO-C3 biomarker in tumor fibrosis studies. Active tumor fibrosis is the leading factor in cold, dense, hypoxic, and collagen-rich tumors. Watch Nicholas Willumsen, Director of Oncology at Nordic Bioscience, discuss how the FDA's endorsement may impact clinical decision-making and patient outcomes. PRO-C3 is measured on the Roche Diagnostics cobas® e automated platform, increasing robustness and accuracy in sample measurements and enabling future in-vitro diagnostic (IVD) use. Morten Karsdal Christina Jensen Neel Ingemann Nissen Jeppe Thorlacius-Ussing Claus S. von Arenstorff Daniel Gabor #FDA #DrugDevelopment #TumorFibrosis #CancerReserach #ClinicalTrials

📢 Role of #GutMicrobiota in #BreastCancer and Drug Resistance 👨🎓 by Sathiyapriya Viswanathan et al. 🔗 Full article: https://lnkd.in/gEjTGQbp In this review article, the authors discuss the impact of the microbiota on breast cancer, with a primary focus on the gut microbiota’s regulation of the breast cancer microenvironment. Ultimately, updates on how #immunotherapy can affect the breast cancer-based #microbiome and further clinical trials on the breast and microbiome axis may be an important piece of the puzzle in better predicting breast cancer risk and prognosis. 👉 This article belongs to the Special Issue: Role of Microorganisms in Breast Cancer https://lnkd.in/gwZ4R-ns